Can umbralisib bring PI3Kδ out of the shadows?

Affiliations

Comment

Jacqueline C Barrientos. Lancet Oncol. 2018 Apr.

. 2018 Apr;19(4):432-434.

doi: 10.1016/S1470-2045(18)30154-2. Epub 2018 Feb 20.

¹ Feinstein Institute for Medical Research, Zucker School of Medicine, New Hyde Park, NY 11021, USA. Electronic address: jbarrientos@northwell.edu.

No abstract available

Comment on

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA. Burris HA 3rd, et al. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. Lancet Oncol. 2018. PMID: 29475723 Clinical Trial.